[HTML][HTML] Population-based evaluation of the effectiveness of nirmatrelvir–ritonavir for reducing hospital admissions and mortality from COVID-19
Background: A randomized controlled trial involving a high-risk, unvaccinated population
that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir …
that was conducted before the Omicron variant emerged found that nirmatrelvir–ritonavir …
Analysis of all-cause hospitalization and death among nonhospitalized patients with type 2 diabetes and SARS-CoV-2 infection treated with molnupiravir or …
Importance Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …
[HTML][HTML] Real-world experience of the comparative effectiveness and safety of molnupiravir and nirmatrelvir/ritonavir in high-risk patients with COVID-19 in a …
Y Mutoh, T Umemura, T Nishikawa, K Kondo, Y Nishina… - Viruses, 2023 - mdpi.com
Molnupiravir (MOV) and nirmatrelvir/ritonavir (NMV/r) are efficacious oral antiviral agents for
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
patients with the 2019 coronavirus (COVID-19). However, little is known about their …
Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: a systematic review and meta‐analysis of randomized control …
The efficacy of molnupiravir in treating patients with coronavirus disease 2019 (COVID‐19)
has been inconsistent across randomized controlled trials (RCTs). Thus, this meta‐analysis …
has been inconsistent across randomized controlled trials (RCTs). Thus, this meta‐analysis …
Clinical outcomes following treatment for COVID-19 with nirmatrelvir/ritonavir and molnupiravir among patients living in nursing homes
BHM Ma, TCF Yip, GCY Lui, MSM Lai, E Hui… - JAMA Network …, 2023 - jamanetwork.com
Importance Older patients living in nursing homes are at very high risk of mortality after
getting COVID-19. Objective To evaluate outcomes following oral antiviral treatment for …
getting COVID-19. Objective To evaluate outcomes following oral antiviral treatment for …
[PDF][PDF] Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits
J Hammond, H Leister-Tebbe, A Gardner… - Open Forum …, 2022 - forumresearch.org
Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and
Other Medical Visits* Page 1 Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related …
Other Medical Visits* Page 1 Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related …
The impact of nirmatrelvir-ritonavir in reducing hospitalizations among high-risk patients with SARS-CoV-2 during the omicron predominant era
MM Al-Obaidi, AB Gungor, S Murugapandian… - The American Journal of …, 2023 - Elsevier
Background The coronavirus disease 2019 (COVID-19) pandemic has caused significant
morbidity and mortality in high-risk populations. Several therapeutics have been developed …
morbidity and mortality in high-risk populations. Several therapeutics have been developed …
Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China …
X Han, C Li, X Yuan, J Cui, Z Han, J Meng… - Annals of …, 2024 - Taylor & Francis
Background The effectiveness of nirmatrelvir–ritonavir has mainly been shown in non-
hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19). The real …
hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19). The real …
Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month …
KL Bajema, K Berry, E Streja, N Rajeevan… - Annals of internal …, 2023 - acpjournals.org
Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
Nirmatrelvir-ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to COVID-19 complications
CR Dormuth, JD Kim, A Fisher, J Piszczek… - JAMA network …, 2023 - jamanetwork.com
Importance Postmarket analysis of individuals who receive nirmatrelvir and ritonavir
(Paxlovid [Pfizer]) is essential because they differ substantially from individuals included in …
(Paxlovid [Pfizer]) is essential because they differ substantially from individuals included in …